Correction, October 24, 2026: An earlier version of this article said SB 906’s trigger applies only to crystalline-polymorph psilocybin and that the law tracks Compass Pathways’ patent estate. As enacted, the trigger covers an FDA-approved and DEA-rescheduled drug containing either an organic psilocybin substance or crystalline-polymorph psilocybin; the polymorph-only wording appears in the bill’s title and its introduced version. The article has been revised.

A new West Virginia law is being read as a state-level prescription pathway for psilocybin that gets out ahead of federal scheduling. It is closer to the reverse. SB 906 keeps psilocybin a Schedule I substance under state code. It adds a single conditional clause: prescribing, distributing, and marketing a drug containing either an organic psilocybin substance or crystalline-polymorph psilocybin becomes lawful only if the Food and Drug Administration approves such a drug and the Drug Enforcement Administration reschedules it. The law does not run ahead of federal action. It waits for it, and pre-clears state code to fall in line automatically the moment Washington moves. That structure takes a side in how psilocybin access gets built in this country.

What the Law Actually Does

Psilocybin stays Schedule I in West Virginia. The statute layers on an exception that fires only when two federal triggers occur: FDA approval and DEA rescheduling of a drug containing organic psilocybin or crystalline-polymorph psilocybin. After that, prescription, distribution, and marketing become lawful, in line with the FDA’s recommendations. Until both of those happen, nothing changes. No one can prescribe psilocybin in West Virginia under this law today. It is a trigger law, inert until both federal triggers clear, then self-executing. The practical near-term effect is zero, and the reading that it leaps ahead of federal scheduling is backwards: it is explicitly subordinate to it.

Why a law that does nothing yet is still worth reading

Trigger laws are how legislatures place bets cheaply. West Virginia gets to signal support for medical psilocybin at no present cost and with no present access, leaving the hard and contested work to the FDA and the DEA. But the bet it places is specific, and the specificity is the signal. The law aligns the state with one of the two diverging routes to legal psilocybin, and pointedly not the other.

One route is the regulated-access model that Oregon and Colorado built. It operates outside the FDA’s approval process entirely: state-licensed supervised-service centers, trained facilitators, and psilocybin that never requires federal drug approval. The other is the conventional pharmaceutical route, an FDA-approved, DEA-rescheduled psilocybin product prescribed like any other drug. SB 906 is a pure expression of the second model. It does nothing for the supervised-service route and everything, eventually, for the prescription-drug route. It is a state betting that the pharmacy, not the service center, is how psilocybin becomes medicine.

The polymorph language, and what the House changed

As introduced in February, the bill’s trigger covered only “the pharmaceutical composition of crystalline polymorph psilocybin,” phrasing that maps onto the patent estate of Compass Pathways, whose synthetic crystalline psilocybin COMP360 is in Phase 3 for treatment-resistant depression and whose Polymorph A is a central patent claim. The House changed that. A Health and Human Resources Committee amendment inserted “organic psilocybin substance or,” and a floor amendment rewrote the subsection into its enacted form, which covers “a drug that contains, an organic psilocybin substance or the pharmaceutical composition of crystalline polymorph psilocybin.” Only the bill’s title still refers to the polymorph alone.

So the enacted law does not track any one company’s patents. COMP360 remains the most advanced candidate to clear the trigger, but an FDA-approved psilocybin drug derived from organic sources would qualify too. What favors the pharmaceutical model is the federal approval requirement, not the crystal form.

What SB 906 Doesn’t Do Yet

The near-term impact is nil, and that bears repeating against any headline suggesting the state legalized prescription psilocybin. The entire mechanism is contingent on two federal actions that have not happened, FDA approval and DEA rescheduling, since COMP360 remains in Phase 3. The law is inert until both do. And a single state’s trigger law is a small data point. West Virginia is reported to join only a small group of states building prescription-oriented laws like this one, a trend still forming, not yet established.

Which Side West Virginia Picked

SB 906 is, for now, a law that does nothing, and its importance is entirely as a marker. It shows a conservative state choosing the FDA-prescription model of psilocybin over the regulated-access model. The law pre-clears the pharmaceutical pathway while leaving the supervised-service route untouched, through a federal approval requirement that favors companies, Compass chief among them, building FDA-approved psilocybin products. The bifurcation of psilocybin access, pharmaceutical prescription on one side and state-regulated service on the other, is one of the defining questions facing the field. Trigger laws like this one are how states are quietly casting their votes. The claim that West Virginia legalized prescription psilocybin is wrong twice over. It legalized nothing yet, and what it conditionally enabled is alignment with the federal approval process and the pharmaceutical model that process favors. Access itself is still years away. The states are beginning to choose sides in how psilocybin will be sold, and the prescription model, the one that runs through the FDA, just picked up another vote.